Humanized GPVI Antibodies Inhibit Platelet Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GPVI-specific antibodies for treating thrombotic and vascular disorders have limitations such as immunogenicity, weak affinity, short half-life, and unfavorable functional properties, including the risk of inducing GPVI depletion and platelet activation, which are not suitable for clinical use in humans.
Innovation Solution
Development of novel human antibodies or antibody fragments with specific modifications, particularly at the C-terminus of the Fab heavy chain, that exhibit high affinity and safety profiles, binding to human and non-human primate GPVI, and inhibit collagen-induced platelet aggregation with an IC50 concentration of 27 nM or less, thereby preventing GPVI receptor activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing GPVI-specific antibodies are used to inhibit platelet activation, then thrombotic and vascular disorders can be treated, but immunogenicity and short half-life occur due to animal origin
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the antibody, specifically humanizing the constant region and optimizing the variable region to achieve high affinity binding (KD < 10^-9 M) while reducing immunogenicity. This transforms the antibody from an animal-derived molecule to a human-compatible therapeutic agent.
Solution Approach 2:
The patent creates a humanized version of the antibody that copies the essential binding properties of the original animal antibody while replacing the immunogenic animal-derived sequences with human sequences. This allows the therapeutic effect to be preserved while eliminating the harmful immune response.
2Reliability
If existing GPVI-specific antibodies are used to block collagen binding, then platelet aggregation is inhibited, but weak affinity and short half-life limit their clinical utility
Solution Approach 1:
The patent optimizes multiple parameters simultaneously: affinity (KD < 10^-9 M), half-life (> 24 hours), and functional properties. This is achieved through systematic modification of the antibody structure, particularly in the CDR regions and constant domain, to achieve sustained therapeutic effect.
3Reliability
If existing GPVI-specific antibodies are used to treat thrombotic disorders, then collagen-induced platelet aggregation is inhibited, but GPVI depletion and platelet activation occur which are irreversible and unsafe
Solution Approach 1:
The patent applies local quality by designing the antibody to bind specifically to the collagen-GPVI interface with precise spatial orientation. The antibody structure is optimized to block the collagen binding site without triggering conformational changes that lead to GPVI depletion or platelet activation, achieving selective inhibition.
Solution Approach 2:
The antibody is designed to preemptively block collagen binding to GPVI before the interaction can trigger downstream signaling pathways that lead to platelet activation and GPVI depletion. This preliminary blocking action prevents the harmful cascade from initiating.
4Reliability
If existing GPVI-specific antibodies are used for therapeutic purposes, then thrombus formation can be inhibited, but animal origin and lack of cross-reactivity to human GPVI make them unsuitable for clinical use
Solution Approach 1:
The patent creates an antibody with universal applicability by ensuring it binds to human GPVI with high affinity and specificity. The humanized design allows the antibody to function across different species models while maintaining optimal binding to human targets, enabling both preclinical research and clinical therapeutic use.
Data Source
AI summary
The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.